Bvf Inc Phathom Pharmaceuticals, Inc. Transaction History

Bvf Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $5.11 Million - $7.34 Million	-150,787 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$33.22 - $50.26 $5.69 Million - $8.61 Million	-171,311 Reduced 53.19%	150,787 $5.01 Million
Q2 2020 Aug 14, 2020	SELL	$25.06 - $54.6 $8.88 Million - $19.4 Million	-354,463 Reduced 52.39%	322,098 $10.6 Million
Q1 2020 May 15, 2020	SELL	$24.65 - $42.83 $2.69 Million - $4.68 Million	-109,290 Reduced 13.91%	676,561 $17.5 Million
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $14.6 Million - $29.6 Million	785,851 New	785,851 $24.5 Million

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $319M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.